MSD provides blockbuster drug free of charge for Evaxion's combination trial
US-based pharmaceutical firm MSD has allowed its drug Keytruda to be used for a phase IIb trial conducted by Evaxion. The Danish biotech company will test its own lead candidate against melanoma in combination with MSD's multi-blockbuster drug.
BY ULRICH QUISTGAARD, TRANSLATED BY DANIEL PEDERSEN
Before the end of the year, Evaxion will begin its phase IIb trial of its lead candidate EVX-01 against metastatic melanoma in a partnership with US-based MSD.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
IO Biotech prepares for IPO in the US
For subscribers
IO Biotech begins phase III trial with partner MSD
For subscribers
